Ofloxacin and Glucose Injection

[Pharmacology and Toxicology] It works by inhibiting bacterial prokaryotic cell DNA gyrase and DNA replication. Due to its unique mechanism of action, it has the characteristics of a broad antibacterial spectrum and strong antibacterial activity, and has a strong antibacterial effect on both Gram-positive and Gram-negative bacteria. It is effective for infections such as Staphylococcus aureus, Streptococcus pyogenes, Streptococcus pyogenes, Enterococcus, Pneumococcus, Escherichia coli, Citrobacter, Klebsiella pneumoniae, Enterobacter, Serratia, Proteus, Pseudomonas aeruginosa, Haemophilus influenzae, Acinetobacter, Campylobacter, Peptostoreptococus, Chlamydia and other sensitive strains. There is no cross-resistance between this product and other antibacterial drugs.

Ofloxacin.

Slightly yellowish green clear liquid.

It is mainly used for acute and chronic bacterial infections of the lower respiratory tract, urogenital system, digestive system, skin and soft tissue caused by sensitive bacteria, as well as urethritis and cervicitis caused by gonococci and Chlamydia trachomatis.

Intravenous drip. Adults: 0.2g each time, twice a day; severe cases: 0.4g each time or as directed by a doctor.

Insomnia, headache, dizziness, nausea, vomiting, diarrhea, rash, elevated serum alanine aminotransferase, and local irritation at the injection site may occur occasionally, but they are generally tolerated and disappear after drug discontinuation.

It is contraindicated for patients who are allergic to this drug or quinolones, patients under 18 years of age, pregnant women, lactating women, and patients with central nervous system damage or epilepsy.

1. Urine alkalinizing agents can reduce the solubility of this product in urine, leading to crystalluria and nephrotoxicity. 2. When quinolone antibiotics are used in combination with theophylline, competitive inhibition of the cytochrome P450 binding site may lead to a significant reduction in the liver clearance of theophylline, a prolonged blood elimination half-life (t1/2?), an increase in blood drug concentration, and the appearance of symptoms of theophylline poisoning, such as nausea, vomiting, tremor, restlessness, excitement, convulsions, palpitations, etc. Although this product has a small metabolism of theophylline, theophylline blood drug concentration should still be measured and the dosage adjusted when used in combination. 3. When this product is used in combination with cyclosporine, the blood drug concentration of cyclosporine can be increased. The blood concentration of cyclosporine must be monitored and the dosage adjusted. 4. When this product is used in combination with the anticoagulant warfarin, although the anticoagulant effect of the latter is slightly enhanced, the patient's prothrombin time should also be closely monitored when used in combination. 5. Probenecid can reduce the secretion of this product from the renal tubules by about 50%. When used together, it may cause toxicity due to the increase in the blood concentration of this product. 6. This product can interfere with the metabolism of caffeine, thereby reducing the clearance of caffeine, prolonging the blood elimination half-life (t1/2beta;), and may cause central nervous system toxicity.

Keep away from light and store in a sealed container.

100ml: Ofloxacin 0.2g and glucose 5.0g

Sichuan QILI Pharmaceutical Co., Ltd.

• Founded in:

  2001-09-24

• Address:

  No. 6 Tianhong Road, High-tech Zone, Chengdu

• Tax NO.:

  91510000MA61Y0AT5F

• Registered Funds:

  60 million yuan

• Website:

  Log in to view

• Email:

  Log in to view